Long intergenic non-protein coding RNA, muscle differentiation 1 (LINC-MD1) (LINC-MD1)

Long intergenic non-protein coding RNA, muscle differentiation 1 (LINC-MD1) is a muscle-specific long non-coding RNA (lncRNA) essential for the proper execution of the myogenic program. It acts as a competing endogenous RNA (ceRNA) by sequestering miR-133 and miR-135, thereby upregulating the expression of master myogenic transcription factors such as MAML1 and MEF2C (Cesana et al., 2011, Cell). Additionally, LINC-MD1 serves as a molecular scaffold, interacting with the RNA-binding protein HuR and the E3 ubiquitin ligase Dzip3 to regulate the stability and localization of myogenic transcripts (Legnini et al., 2014, Nature Communications). In pathological states like Duchenne muscular dystrophy (DMD), LINC-MD1 levels are markedly reduced, leading to impaired muscle regeneration and accelerated disease progression (NCBI Gene: 100874014). Targeting the interaction between LINC-MD1 and Dzip3 represents a novel therapeutic approach to restore the balance of myogenic factors in muscle-wasting diseases. Current research explores the use of antisense oligonucleotides and small molecules to modulate these lncRNA-protein interactions, though clinical applications remain in the early stages of development. The disruption of the LINC-MD1–Dzip3 complex specifically aims to prevent the degradation or sequestration of the lncRNA, ensuring its availability for myogenic signaling. This target is particularly relevant for precision medicine in neuromuscular disorders where RNA-protein networks are dysregulated.

Other names

LINCMD1LINC00033NCRNA00033Long intergenic non-protein coding RNA 33

Disruption of the LINC-MD1–Dzip3 interaction to modulate the myogenic regulatory network and enhance muscle regeneration.